Is Buying UROLOGIX INC (OTCMKTS:ULGX), Having Lower Short Interest a Winning Strategy?

August 18, 2018 - By Vernon Prom

Investors sentiment decreased to 0 in 2018 Q1. Its down Infinity, from Infinity in 2017Q4. It turned negative, as 0 investors sold Urologix, Inc. shares while 0 reduced holdings. 0 funds opened positions while 0 raised stakes. 60,521 shares or 0.00% without change from 60,521 shares in 2017Q4 were reported.
Mairs Pwr Inc owns 20,000 shares. Gemmer Asset Management Limited Liability Corp accumulated 40,521 shares or 0% of the stock.

The stock of UROLOGIX INC (OTCMKTS:ULGX) registered a decrease of 7.45% in short interest. ULGX’s total short interest was 38,500 shares in August as published by FINRA. Its down 7.45% from 41,600 shares, reported previously. With 286,700 shares average volume, it will take short sellers 0 days to cover their ULGX’s short positions.

It closed at $0.0083 lastly. It is down 0.00% since August 18, 2017 and is . It has underperformed by 12.57% the S&P500.

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia in the United States. The company has market cap of $176,640. The firm offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It currently has negative earnings. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.